WallStSmart

Ke Holdings Inc (BEKE)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ke Holdings Inc generates 1321599% more annual revenue ($90.14B vs $6.82M). BEKE leads profitability with a 3.8% profit margin vs -40.7%. BEKE earns a higher WallStSmart Score of 58/100 (C).

BEKE

Buy

58

out of 100

Grade: C

Growth: 6.7Profit: 4.5Value: 5.3Quality: 7.5
Piotroski: 4/9Altman Z: 2.02

EUDA

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -47.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BEKESignificantly Overvalued (-19.7%)

Margin of Safety

-19.7%

Fair Value

$15.74

Current Price

$16.08

$0.34 premium

UndervaluedFair: $15.74Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BEKE4 strengths · Avg: 9.3/10
PEG RatioValuation
0.4910/10

Growing faster than its price suggests

EPS GrowthGrowth
54.2%10/10

Earnings expanding 54.2% YoY

Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

Debt/EquityHealth
-0.5610/10

Conservative balance sheet, low leverage

Areas to Watch

BEKE4 concerns · Avg: 3.0/10
P/E RatioValuation
36.3x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
5.3%3/10

ROE of 5.3% — below average capital efficiency

Profit MarginProfitability
3.8%3/10

3.8% margin — thin

Revenue GrowthGrowth
-19.0%2/10

Revenue declined 19.0%

EUDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$48.09M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-2.53M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BEKE

The strongest argument for BEKE centers on PEG Ratio, EPS Growth, Debt/Equity. PEG of 0.49 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : BEKE

The primary concerns for BEKE are P/E Ratio, Return on Equity, Profit Margin. Thin 3.8% margins leave little buffer for downturns.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BEKE profiles as a value stock while EUDA is a hypergrowth play — different risk/reward profiles.

EUDA carries more volatility with a beta of 0.64 — expect wider price swings.

EUDA is growing revenue faster at 78.9% — sustainability is the question.

Monitor REAL ESTATE SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BEKE scores higher overall (58/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ke Holdings Inc

REAL ESTATE · REAL ESTATE SERVICES · China

KE Holdings Inc. is involved in the operation of an integrated online and offline platform for housing transactions and services in the People's Republic of China. The company is headquartered in Beijing, China.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a biopharmaceutical innovator dedicated to the discovery, development, and commercialization of transformative therapies for rare diseases and unmet medical needs. The company utilizes cutting-edge technologies and maintains a strong clinical pipeline, emphasizing supportive care and immune modulation. With a deep commitment to research and development, EUDA is strategically positioned to drive healthcare advancements, improve patient outcomes, and broaden access to vital medical treatments.

Visit Website →

Want to dig deeper into these stocks?